Abstract
Background: Solid lipid nanoparticles are a colloidal carrier system for topical, oral, and parenteral administration that are utilized to increase the bioavailability of mostly lipophilic medications. Mesalamine is an anti-inflammatory drug that works in inflammatory bowel disease and is structurally similar to salicylates. In the current study, glycerylmonostearate was used as a lipid, Tween 80 as a surfactant, and cremophor as a solubilizing agent to enhance the formulation, evaluation, and stability studies of mesalamine-loaded solid lipid nanoparticles. Results: Particle size, entrapment efficiency, scanning electron microscopy, and differential scanning calorimetry were used to characterize the formulations. The drug concentration in the MES-SLNs F-7 was found to be 334mg in a 100ml solution of SLNs, and the size of the MES-SLNs F-7 was 82.1±5.37nm. the zeta potential was -13.9mV, the polydispersity index was 0.35 0.15, and the formulated MES-SLNs showed burst release. The physical stability of the formulated MES-SLNs was determined by measuring the size of the MES-SLNs, and colour stored at four different temperatures (-20C, 40C, room temperature, and 400C) for three months. High Performance Liquid Chromatographic analysis was used to determine the MES-SLNs' chemical stability. At -20°C and 40°C, it was discovered that MES-SLNs were stable. Conclusion: The chemical stability of MES-SLNs was determined by HPLC analysis. It was found that MES-SLNs were stable at -20C and 40ºC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.